Results of a study conducted by ZS Associates designed to benchmark incentive practices in the pharmaceutical and biotech industries revealed an increase of 8% in total target compensation in 2009, and that variable pay as a percentage of overall target compensation remained constant at 25%.
Aptilon announced the availability of an expanded set of tools that enables biopharmaceutical companies to increase access to valuable, high-prescribing physicians.
inVentiv Selling Solutions, will begin providing a sales personnel to Keltman Pharmaceuticals, a wholesale pharmaceutical company specializing in re-packaged medications for physician dispensing.
GfK launched Brand BEAT (Brand Equity Assessment & Tracking), a complete package of healthcare-specific brand positioning diagnostic tools for measuring the cognitive and emotional strengths of a brand.
Torre Lazur McCann Healthcare Group was named AOR for Entereg–the first and only FDA-approved agent indicated to accelerate the time to upper and lower GI recovery following partial large or small bowel resection surgery with primary anastomosis.
Amgen and GlaxoSmithKline (GSK) announced plans to share commercialization of Amgen’s osteoporosis drug denosumab, in Europe, Australia, New Zealand and Mexico once they win approval in those countries.
Effient launch poses puzzle for Lilly, Daiichi Sankyo
Epocrates introduced a new OTC drug module that will allow clinicians to access the latest information for hundreds of brand name OTC drugs from their iPhone, BlackBerry, Palm or Windows device.
The Office of Compliance and Biologics Quality (OCBQ) in the FDA’s Center for Biologics Evaluation and Research (CBER) has sent a warning letter to Baxter regarding the company’s promotional material for Tisseel general surgery brochure.